



**I-MAB**  
BIOPHARMA

## **I-Mab Filed 2020 Annual Report on Form 20-F**

April 28, 2021

SHANGHAI and GAITHERSBURG, Md., April 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission ("SEC") on April 28, 2021.

The annual report is available on the Company's investor relations website at [ir.i-mabbiopharma.com](http://ir.i-mabbiopharma.com) and on the SEC's website at [www.sec.gov](http://www.sec.gov). The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon written request. Requests should be directed to Investor Relations, I-Mab, Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai 201210, People's Republic of China.

### **About I-Mab**

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit <http://ir.i-mabbiopharma.com> and follow I-Mab on [LinkedIn](#), [Twitter](#) and [WeChat](#).

### **For more information, please contact:**

#### **I-Mab**

Jielun Zhu, Chief Financial Officer

E-mail: [jielun.zhu@i-mabbiopharma.com](mailto:jielun.zhu@i-mabbiopharma.com)

Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer

E-mail: [gigi.feng@i-mabbiopharma.com](mailto:gigi.feng@i-mabbiopharma.com)

Office line: +86 21 6057 5785

#### **Investor Inquiries:**

*The Piacente Group, Inc.*

Emilie Wu

E-mail: [emilie@thepiacentegroup.com](mailto:emilie@thepiacentegroup.com)

Office line: +86 21 6039 8363

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/i-mab-filed-2020-annual-report-on-form-20-f-301279034.html>

SOURCE I-Mab